Glaxo Wellcome Ziagen
Executive Summary
Company begins enrollment of patients March 23 in an expanded access program for the anti-HIV therapy abacavir. Patients will receive Ziagen twice daily free of charge and will be encouraged to use other therapies to which they have not been exposed. Qualifying patients are those failing or intolerant to standard therapy, older than 13 and unable to construct a viable treatment regimen without Ziagen. An adult open label program in the U.S. has enrolled 1,900 patients and safety data have been collected on more than 3,000 patients. Approximately 3% of Ziagen patients have experienced a hypersensitivity reaction, and Glaxo warns that those patients should not take Ziagen again because it could be fatal. The company expects to file an NDA by mid-year...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth